Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).

Phase 1

Completed

• Conditions: Mitochondrial Myopathies; Mitochondrial Encephalomyopathies; Mitochondrial Diseases; MELAS; MERRF
• Interventions: Behavioral: Promoting Resilience in Stress Management (PRISM); Behavioral: Clinical-focused narrative (CFN)

• Registration Number: NCT06051448
• Lead Sponsor: Children's Hospital of Philadelphia

Brief Summary

The goal of this study is to find the best way to help people with primary mitochondrial disease deal with the stress of their condition, and to help these people be better able to "bounce back," or be resilient. In order to do this, the investigators are going to test two interventions (an intervention means that it aims to change something): Promoting Resilience in Stress Management (PRISM) and clinical-focused narrative (CFN) intervention.

Detailed Description

The investigators are going to test two interventions in this pilot study. The first is called Promoting Resilience in Stress Management (PRISM). The second is called clinical-focused narrative (CFN) intervention. These interventions involve talking with the researcher about several specific topics.

Participants will join six virtual study visits. They will be assigned to the PRISM group or the CFN group. During the first study visit, participants will learn about the study and will fill out consent forms if they want to participate. In the next four visits, participants will receive one of the study interventions (PRISM or CFN). Some interventions will be supported with a digital app for participants to track progress and review what was talked about in the intervention. The sixth virtual study visit will be a discussion group that happens a couple months after participants finish the intervention.

Participants will also be sent several surveys to complete. One set of surveys is sent just once after the participant enrolls in the study. Another set of surveys is sent after the participant enrolls and again after the participant finishes the interventions.

The study team will review participants' medical records to confirm they have primary mitochondrial disease and to review the genetic diagnosis. If participants do not have copies of their own medical records or if the study team does not already have access to them, the study team will ask participants to sign a release form to obtain a copy of the medical records and/or genetic testing report.

Study Timeline

• Study First Submitted: 2023-09-12
• Study First Submitted QC: 2023-09-12
• Study Start: 2023-09-22
• Study First Posted: 2023-09-25
• Primary Completion: 2024-02-28
• Study Completion: 2024-02-28
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-26
• Last Update Posted: 2024-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Males or females at least 18 years old
2. Capable of giving consent, or there is a legally authorized representative capable of giving consent on the subject behalf and if appropriate, assent.
3. Able to speak and read English
4. Able to participate in Web- and App-based interventions
5. Confirmed molecular diagnosis of primary mitochondrial disease

Read More

Exclusion Criteria

1. Suspected but no molecular diagnosis primary mitochondrial disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Promoting Resilience in Stress Management (PRISM)	Promoting Resilience in Stress Management (PRISM)	-
Clinical-focused narrative (CFN)	Clinical-focused narrative (CFN)	-

Primary Outcome Measures

Name	Time	Method
Determine change in mean in scores on validated scale assessing resilience between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Connor-Davidson Resilience Scale (CD-RISC) is a validated measure to assess resilience. Possible scores range from 0-100 (higher scores reflecting greater resilience). Mean scores calculated on scales administered before the intervention will be compared to mean scores on scales administered after completion of the intervention.
Determine variability in scores on validated scale assessing resilience between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Connor-Davidson Resilience Scale (CD-RISC) is a validated measure to assess resilience. Possible scores range from 0-100 (higher scores reflecting greater resilience). Variability in scores of scales collected before starting and after completion of the interventions will be calculated.
Determine mean scores on validated scale assessing quality of life in those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The 36-Item Short Form Survey Instrument (SF-36) is a validated measure to assess quality of life. Possible scores range from 0-100 (higher scores reflect a more favorable health state). Mean scores calculated on scales administered before the intervention will be compared to mean scores on scales administered after completion of the intervention.
Determine mean score on validated scale assessing resilience in those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Connor-Davidson Resilience Scale (CD-RISC) is a validated measure to assess resilience. Possible scores range from 0-100 (higher scores reflecting greater resilience). Mean scores will be calculated on scales administered to subjects before the intervention and scales administered after intervention completion.
Determine change in mean scores on validated scale assessing coping between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Family Crisis Oriented Personal Scale (F-COPES) is a validated measure to assess coping. Possible scores range from 30 to 150 (higher scores reflect higher levels of coping and problem-solving ability). Mean scores calculated on scales administered before the intervention will be compared to mean scores on scales administered after completion of the intervention.
Determine variability in scores on a validated scale assessing coping between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Family Crisis Oriented Personal Scale (F-COPES) is a validated measure to assess coping. Possible scores range from 30 to 150 (higher scores reflect higher levels of coping and problem-solving ability). Variability in scores of scales collected before starting and after completion of the interventions will be calculated.
Determine variability in scores on a validated scale assessing quality of life between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The 36-Item Short Form Survey Instrument (SF-36) is a validated measure to assess quality of life. Possible scores range from 0-100 (higher scores reflect a more favorable health state). Variability in scores of scales collected before starting and after completion of the interventions will be calculated.
Determine mean scores on validated scale assessing coping in those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The Family Crisis Oriented Personal Scale (F-COPES) is a validated measure to assess coping. Possible scores range from 30 to 150 (higher scores reflect higher levels of coping and problem-solving ability). Mean scores will be calculated on scales administered to subjects before the intervention and scales administered after intervention completion.
Determine change in mean in scores on validated scale assessing quality of life between those who receive PRISM and those who receive CFN.	Up to 3 months after the first intervention	The 36-Item Short Form Survey Instrument (SF-36) is a validated measure to assess quality of life. Possible scores range from 0-100 (higher scores reflect a more favorable health state). Mean scores will be calculated on scales administered to subjects before the intervention and scales administered after intervention completion.

Secondary Outcome Measures

Name	Time	Method
Explore participant experience with PRISM and CFN and assess their acceptability among adults with primary mitochondrial disease.	Three months after completing the intervention, discussion groups will occur.	Semi-structured interviews will be conducted at discussion groups.

Trial Locations

Locations (1)

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States